Scott LaNeve, General ManagerDRUGSCAN's impressive 37-year track record in toxicology testing is a testament to its exceptional ability to adapt and respond to evolving market demands. This agility has enabled it to stay ahead of the curve in an ever-evolving industry and provide cutting-edge solutions that meet its customers' shifting needs.
"We follow the Lean Six Sigma approach to continuously improve our lab operations. We work toward our annual goals by setting quarterly objectives, which allow us to stay focused on our goals, monitor progress, and make necessary adjustments to enhance processes," says Scott LaNeve, General Manager of DRUGSCAN.
Since its inception as a forensic toxicology lab, DRUGSCAN has grown exponentially to become a recognized leader and pioneer in providing various services, including toxicology testing, pre- and post-employment drug testing, Department of Transportation (DOT) testing, and other testing services related to legal matters, to cater to diverse client needs.
One of the key technologies that drives DRUGSCAN's success is its cutting-edge informatics, which integrates patients' pharmacy data with their test results to provide caregivers with a more comprehensive understanding of the patient’s overall health. In addition, it has developed tools that seamlessly integrate with electronic medical records to help healthcare providers consistently comply with opioid prescription guidelines.
DRUGSCAN's commitment to innovation and continuous improvement is evident in its investment in advanced technologies, which allows for highly accurate and reliable toxicology testing. Its emphasis on innovative technologies also plays a critical role in assisting healthcare providers, health systems, and other medical labs with quick turnaround times. Backed by these unmatched capabilities, DRUGSCAN is proven to help care providers effectively treat patients who are on controlled substances or those who struggle with substance use disorders, with a 97 percent success rate of notifying physicians within 48 hours.
This approach to prioritizing the development of its employees has driven its reputation as one of the top workplaces in the U.S. It is known to implement career advancement opportunities for its staff and continually strives to get their feedback to maintain high levels of workforce engagement and productivity. Above all, DRUGSCAN strongly emphasizes patient-focused toxicology testing, allowing for early identification of medication misuse. Providing this information in the most simplified form allows for early interventions and ultimately better outcomes for patients.
We follow the Lean Six Sigma approach to continuously improve our lab operations. We work toward our annual goals by setting quarterly objectives, which allow us to stay focused on our goals, monitor progress, and make necessary adjustments to enhance processes
DRUGSCAN's state-of-the-art laboratory is one of only ten commercial labs in the U.S. that have received a SAMSHA certification. Its most recent CAP inspection showed no findings and no deficiencies which affirms DRUGSCAN's dedication to providing superior lab services and instils trust and confidence in its customers.
At the heart of DRUGSCAN's unmatched competencies is its core belief in building strong connections with customers. A critical service that illustrates this mindset is that providers have direct access to DRUGSCAN’s toxicologists to discuss test results and the impact of such results on a patient’s treatment. Similarly, its leaders are deeply invested in the national patient care conversation and frequently give talks across the U.S. These discussions, often related to developing relevant tests and novel psychoactive compounds, are usually held in the Pacific Northwest, the Midwest, and the Mid-Atlantic regions.
Recently, DRUGSCAN became one of the few laboratories in the country capable of testing for the presence of Xylazine, a veterinary compound frequently found as an adulterant in illicit drugs. Xylazine is causing a major concern across the U.S. due to its hazardous and potentially fatal side effects which led to DRUGSCAN’s decision to develop the testing. Unlike other labs who use new testing as a marketing opportunity, DRUGSCAN works hard to ensure it only offers testing that will lead to better patient outcomes. This achievement is one of the many examples of DRUGSCAN's unwavering dedication to providing timely, relevant, and actionable testing services to its clients, further solidifying its position as a leader in the industry.
